OptimizeRx President & CSO Miriam Paramore to retire, transition to advisor role

OptimizeRx Corp

Paramore retires as President & CSO effective Dec 31, 2021; will advise through July 31, 2022.
Her option grants continue vesting during advisory term; she receives full 2021 cash bonus.
Ed Stelmakh joined as CFO/COO; new exec team includes Febbo, Stelmakh, Silvestro, Inman, Odence-Ford.
Company cites 45% 3-year CAGR and ~$1B market cap; succession planned, functions transitioned.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Miriam Paramore

President & Chief Strategy Officer

OPRX · OptimizeRx Corp

Effective: 2021-12-31
Filed: December 22, 2021, 6:59 PM ET

Ms. Paramore will retire as President & Chief Strategy Officer of the Company effective as of December 31, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miriam Paramore departed as President & Chief Strategy Officer at OptimizeRx Corp.

Action: will retire
Role: President & Chief Strategy Officer

Exact text from the filing

Ms. Paramore will retire as President & Chief Strategy Officer of the Company effective as of December 31, 2021

View on SEC.gov

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-21-067049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.